- Company
- Big5 general hospitals codes in 2nd PARP inhibitor Zejula
- by Eo, Yun-Ho Apr 6, 2020 06:28am
- The world’s second poly ADP-ribose polymerase (PARP) inhibitor Zejula’s drug code has been implemented by Big 5 general hospitals in Korea. A pharmaceutical industry source reported an ovarian cancer treatment by Takeda Pharmaceuticals Korea, Zejula (niraparib) has been registered by drug committees (DC) around 24 general hospitals so f
- Company
- Otsuka is setting new records for sales & operating profit
- by An, Kyung-Jin Apr 6, 2020 06:27am
- Korea Otsuka Pharmaceutical has achieved the best performance since its launch last year. Although the sales of healthcare products were low due to the boycott of Japanese-made products, sales of professional medicines surged, setting new records for both sales and operating profit According to the audit report of Korea Otsuka Pharmaceutical,
- Company
- GC Pharma: all capacity focused on COVID-19
- by Kim, Jin-Gu Apr 6, 2020 06:26am
- The GC Corporations Group says ‘all hands on deck’ to fight against COVID-19. The group has a plan to cover all&8212;from diagnostics to preventive and treatment&8212;with the group’s test kit, vaccine and specialized treatment. On Apr. 2, GC Pharma disseminated a press release and announced “The company would commercialize a plas
- Company
- KRPIA demands transferred originals evade pricing reduction
- by Eo, Yun-Ho Apr 3, 2020 06:36am
- The pharmaceutical industry is firmly opposing to the Korean government’s decision to apply stepped pricing system on transferred original drugs. Sources reported Korean Research-based Pharmaceutical Industry Association (KRPIA) has delivered an official statement to Health Insurance Review and Assessment Service (HIRA) on Apr. 2, deman
- Company
- FMC-Korea, names Hee-gyeong Kim as new CEO
- by An, Kyung-Jin Apr 3, 2020 06:34am
- FMC Korea has replaced its representative for the first time since its establishment in Korea. FMC Korea said that it has appointed Hee-gyeong Kim as the new chief executive officer effective on April 1. This is the first time the company has replaced the CEO since the establishment of a domestic corporation in 1997. Former CEO Seong-ok
- Company
- Daxas' generic by Sama succeeded in patenting
- by Kim, Jin-Gu Apr 2, 2020 06:26am
- Sama Pharm succeeded in avoiding the patent for Daxas (Roflumilast), a treatment for chronic obstructive respiratory disease (COPD). Sama Pharm's success in avoiding this patent attracts attention because large companies have failed in succession. The IPT took the side of a generic company in a trial to confirm the passive scope of the
- Company
- Hemlibra's indications are expanded
- by Nho, Byung Chul Apr 2, 2020 06:25am
- As a global new drug, indications & dosage standards for Hemlibra, a hemophilia preventive drug, have been expanded. JW Pharmaceutical said on the 31st, that Hemlibra (Emicizumab), which dramatically improves the convenience of administration, is additionally approved by the MFDS as a routine preventive therapy for non-antibody patients.
- Company
- GC LabCell to develop COVID-19 treatment using NK cell
- by Lee, Seok-Jun Apr 1, 2020 06:17am
- GC LabCell is developing a COVID-19 treatment using natural killer (NK) cell. The Korean company is tentatively planning to start a clinical trial in Korea and the U.S. later this year. On Mar. 30, GC LabCell announced the company and the U.S.-based biotech company KLEO Pharmaceuticals are collaborating on a research for the COVID-19 trea
- Company
- Samsung Epis, made a surplus of ₩122.5 billion
- by Chon, Seung-Hyun Apr 1, 2020 06:16am
- Samsung Bioepis has made a surplus for the first time since its inception. It has been in deficit every year since its inception in 2012, but it recorded operating profit of &8361;122.5 billion due to the growth of biosimilars in overseas markets. Sales also grew more than twice that of the previous year. According to Samsung Bioepis' audit
- Company
- Xeljanz to be used with caution in thrombosis patients
- by Nho, Byung Chul Mar 30, 2020 06:18am
- Among the indications for Pfizer's JAK inhibitor Xeljanz (Tofacitinib citrate), the standard for 10 mg high dose prescription of ulcerative colitis has changed. Pfizer recently changed the permission, and added that patients with risk factors for thrombosis should avoid using this drug and patients with signs·symptoms of thrombosis should
